• BMN 673 (Talazoparib): PARP1/2 Inhibition at the Frontier...

  2025-10-19

  Explore the advanced mechanisms of BMN 673 (Talazoparib), a potent PARP1/2 inhibitor, in targeting DNA repair deficiencies and PI3K pathway modulation. This article uniquely unpacks the interplay between PARP-DNA complex trapping, homologous recombination deficiency, and therapeutic selectivity for cancer research.

• Crizotinib Hydrochloride: Advancing ALK Kinase Inhibition...

  2025-10-18

  Crizotinib hydrochloride stands out as a small molecule inhibitor for cancer research, enabling high-precision inhibition of ALK, c-Met, and ROS1 kinase-driven oncogenic pathways in complex, patient-derived tumor models. Its integration into assembloid workflows is transforming experimental cancer biology, powering robust, physiologically relevant drug screening and resistance mechanism discovery.

182 records 13/13 page Previous First page 上5页 111213